Gilead Sciences, Inc. (GILD)

Last Price:  

Company Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $24.69B
Net Income (Most Recent Fiscal Year) $123.00M
PE Ratio (Current Year Earnings Estimate) 8.71
PE Ratio (Trailing 12 Months) 8.85
PEG Ratio (Long Term Growth Estimate) 0.70
Price to Sales Ratio (Trailing 12 Months) 3.19
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 4.32
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 7.54
Pre-Tax Margin (Trailing 12 Months) 6.76%
Net Margin (Trailing 12 Months) 0.50%
Return on Equity (Trailing 12 Months) 47.14%
Return on Assets (Trailing 12 Months) 14.63%
Current Ratio (Most Recent Fiscal Quarter) 1.40
Quick Ratio (Most Recent Fiscal Quarter) 1.26
Debt to Common Equity (Most Recent Fiscal Quarter) 1.85
Inventory Turnover (Trailing 12 Months) 3.87
Book Value per Share (Most Recent Fiscal Quarter) $14.54
Earnings per Share (Most Recent Fiscal Quarter) $2.19
Earnings per Share (Most Recent Fiscal Year) $7.09
Diluted Earnings per Share (Trailing 12 Months) $0.08
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - General
Common Shares Outstanding 1.26B
Free Float 1.25B
Market Capitalization $78.85B
Average Volume (Last 20 Days) 7.36M
Beta (Past 60 Months) 0.40
Percentage Held By Insiders (Latest Annual Proxy Report) 0.13%
Percentage Held By Institutions (Latest 13F Reports) 75.81%
Annual Dividend (Based on Last Quarter) $2.72
Dividend Yield (Based on Last Quarter) 4.33%